WellSpring Pharmaceutical Corporation Announces Hire of Wayne Miller as Vice President, Sales & Marketing, Consumer Brands
Published: Nov 07, 2008
BRADENTON, Fla., Nov. 7 /PRNewswire/ -- WellSpring Pharmaceutical Corporation, a growing North American-based pharmaceutical manufacturer, today announced that Wayne Miller has been hired as the Vice President, Sales and Marketing, Consumer Brands.
Mr. Miller, an accomplished sales executive, will be responsible for designing and implementing the Company's sales and marketing strategy in the United States for its newly acquired over-the-counter product line, which includes Micatin (R) (antifungal), Emetrol (R) (anti-nausea), and Gelusil (R) (antacid). Mr. Miller will also lead the United States launch of two products that the Company currently markets in Canada, Glaxal Base(TM) and Barriere.
Mr. Miller most recently held the position of Vice President, Sales and Marketing for a North American based over-the-counter consumer health company, Origin BioMed. During his tenure with Origin BioMed, Mr. Miller was the driving force behind the successful launch of products into North America, gaining entry into several national and regional drug chains, as well as negotiating viable relationships with the North American drug wholesalers, including AmerisourceBergen, McKesson and Cardinal Health.
Along with his team at Origin BioMed, Mr. Miller was recently awarded a Nova Scotia Professional Sales Award for Innovative Sales Team. These awards honor polished professional salespeople who are changing the perception of the profession and are the driving force behind their organization's success.
"Mr. Miller is a valuable addition to our team. We are pleased to have him lead our Consumer Brands Sales and Marketing group," said Dr. Robert Vukovich, WellSpring's CEO and President. "His leadership experience, coupled with an innovative and energetic approach, makes him ideally suited to direct and guide our consumer health business."
About the Company
WellSpring Pharmaceutical Corp. has made the development, marketing and sales of new and novel prescription and OTC drug products its strategic focus. WellSpring's prescription drug products include Dyrenium (R) (diuretic) and Dibenzyline (R) (anti-hypertension) which are marketed in the US. The firm is an active acquirer of pharmaceutical brands and enhances their value through the development of product improvements and line extensions.
WellSpring is a privately held pharmaceutical company founded in 1999 by Dr. Robert A. Vukovich the firm's CEO and Chairman. Dr. Vukovich previously founded and managed Roberts Pharmaceutical Corporation of Eatontown, NJ until its acquisition by Shire Pharmaceutical Group in 1999. WellSpring owns and operates an FDA approved manufacturing plant in Oakville, Ontario, Canada. Its administrative headquarters are located in Bradenton, Florida. The firm provides contract manufacturing services to the pharmaceutical industry and manufactures prescription and OTC drug products for both the US and Canada.
Dr. Robert A. Vukovich, +1-941-552-7880, or +1-941-504-1229, or Wendy Shusko, +1-941-552-7881.
WellSpring Websites: www.wellspringpharm.com, www.wpcoutsourcing.com, www.wellskin.ca.
Information regarding several of the newly acquired brands can be found at the following web addresses: www.micatin.com, www.gelusil.com and www.emetrol.com.
CONTACT: Dr. Robert A. Vukovich, +1-941-552-7880, or +1-941-504-1229, or
Wendy Shusko, +1-941-552-7881, both for WellSpring Pharmaceutical
Web site: http://www.wellspringpharm.com/